Drug Profile


Alternative Names: AVP-786; CTP-786; d-DM; Deuterated dextromethorphan plus ultra low dose quinidine; Deuterated DM plus ultra low dose quinidine; Deuterated-dextromethorphan; Deuterated-DM

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Avanir Pharmaceuticals
  • Class Antitussives; Morphinans; Opioid analgesics; Organic deuterium compounds; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; KATP channel inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sigma-1 receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Agitation
  • Phase II Major depressive disorder; Neurodegenerative disorders; Schizophrenia
  • Phase I Neuropathic pain
  • Preclinical Psychiatric disorders

Most Recent Events

  • 31 Mar 2017 Avanir Pharmaceuticals plans a phase II trial for Neurodegenerative disorders in USA (NCT03095066)
  • 14 Feb 2017 Chemical structure information added
  • 01 Dec 2015 Avanir initiates enrolment in a phase III trial for Agitation in patients with dementia of the Alzheimer's type (In adults, In the elderly) in USA (PO) (NCT02446132)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top